Pieris Pharmaceuticals to Present Preclinical Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the ERS International Congress 2018
BOSTON, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that preclinical data for AZD1402/PRS-060 will be presented at two poster sessions at the European Respiratory Society (ERS) International Congress 2018 in Paris, France. PRS-060, an inhaled IL-4 receptor alpha antagonist, the lead candidate in Pieris’ respiratory collaboration with AstraZeneca, is currently in Phase 1 clinical development.
Title: The Discovery and Development of AZD1402/PRS-060 a Potent and Selective Blocker of the IL-4 Receptor alpha
Poster Session: Session 113
Poster Number: PA1047
Date/Time: Sunday September 16, 2018, 12:50 – 2:40 PM CEST
Title: AZD1402/PRS-060, an inhaled Anticalin® IL4-Rα antagonist, potently inhibits IL-4 induced functional effects in human whole blood, which can be employed translationally in clinical studies
Poster Session: Session 536
Poster Number: PA5248
Date/Time: Wednesday September 19, 2018, 8:30 – 10:30 AM CEST
The posters will be made available on the Investor Relations section of the Company’s website at www.pieris.com after their respective poster session.
About Pieris Pharmaceuticals
Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information, visit www.pieris.com.
Forward Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods and our business and product development plans, including the advancement of our proprietary and co-development programs into and through the clinic. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; our ability to address the requests of the FDA; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and the Company's Quarterly Reports on Form 10-Q.